Bristol-Myers Squibb Company (BMY)

Return on assets (ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	8,025,000	8,285,000	7,963,000	7,311,000	6,327,000	6,677,000	6,617,000	6,251,000	6,994,000	-5,405,000	-5,079,000	-6,219,000	-9,015,000	-44,000	-563,000	954,000	3,439,000	5,655,000	6,203,000	5,144,000
Total assets	US$ in thousands	95,159,000	91,263,000	93,489,000	94,281,000	96,820,000	98,196,000	100,357,000	103,034,000	109,314,000	110,893,000	110,797,000	112,435,000	118,481,000	125,536,000	128,076,000	129,285,000	129,944,000	57,433,000	55,163,000	34,834,000
ROA		8.43%	9.08%	8.52%	7.75%	6.53%	6.80%	6.59%	6.07%	6.40%	-4.87%	-4.58%	-5.53%	-7.61%	-0.04%	-0.44%	0.74%	2.65%	9.85%	11.24%	14.77%

December 31, 2023 calculation

ROA = Net income (ttm) ÷ Total assets
= $8,025,000K ÷ $95,159,000K
= 8.43%

The return on assets (ROA) of Bristol-Myers Squibb Co. has shown a generally positive trend over the past eight quarters, indicating increased efficiency in generating profits from its total assets.

In Q4 2023, the ROA was 8.43%, a slightly lower but still favorable performance compared to the previous quarter. This decline may be attributed to various factors such as changes in operating expenses, revenue growth, or asset management.

The company's Q3 2023 ROA was 9.08%, marking a significant improvement compared to the preceding quarter. This strong performance suggests that the company effectively utilized its assets to generate profits during that period.

Q2 2023 also saw a healthy ROA of 8.52%, demonstrating consistent profitability relative to the company's asset base. Q1 2023 had an ROA of 7.75%, indicating a solid performance in generating profits from its assets.

Comparing the latest data to the same quarter of the previous year, there has been substantial growth in ROA. In Q4 2022, the ROA was 6.53%, which has steadily increased over the quarters. This positive trend indicates that Bristol-Myers Squibb Co. has been successful in optimizing its asset utilization to drive profitability.

Overall, Bristol-Myers Squibb Co.'s ROA has shown a positive trajectory over the past few quarters, reflecting efficient management of assets to generate profits. This trend suggests that the company is effectively utilizing its resources to create value for shareholders and stakeholders.